Breaking News Instant updates and real-time market news.

DE

Deere

$123.98

-2.65 (-2.09%)

, EL

Estee Lauder

$98.32

-2.75 (-2.72%)

20:25
08/17/17
08/17
20:25
08/17/17
20:25

Notable companies reporting before tomorrow's open

Notable companies reporting before tomorrow's open, with earnings consensus, include Deere (DE), consensus $1.95... Estee Lauder (EL), consensus 43c... Foot Locker (FL), consensus 90c... Hibbett Sports (HIBB), consensus (20c).

DE

Deere

$123.98

-2.65 (-2.09%)

EL

Estee Lauder

$98.32

-2.75 (-2.72%)

FL

Foot Locker

$47.70

-0.87 (-1.79%)

HIBB

Hibbett Sports

$11.50

-0.3 (-2.54%)

  • 18

    Aug

  • 18

    Aug

  • 18

    Aug

  • 18

    Aug

  • 22

    Nov

DE Deere
$123.98

-2.65 (-2.09%)

08/07/17
08/07/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Deere (DE) upgraded to Conviction Buy from Buy at Goldman Sachs. 2. Chemours (CC) upgraded to Neutral from Sell at UBS with analyst John Roberts saying Chemours' execution has disproved his prior concerns. 3. BP (BP) upgraded to Overweight from Neutral at Piper Jaffray with analyst Guy Baber saying the company's cash flow generation is in the early stages of a "multi-year positive inflection" while Macondo headwinds are subsiding. 4. L3 Technologies (LLL) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Nosh Poponak saying he favors increased exposure to Defense given the current industry cycle position, geopolitics, and Department of Defense budget dynamics. 5. Illumina (ILMN) upgraded to Buy from Hold at Canaccord with analyst Mark Massaro saying he sees a strong upgrade cycle for NovaSeq beginning in the tird quarter and lasting for three years. He believes we remain in the early innings on major waves of cancer growth and expects the continuation of robust growth of direct to consumer products, such as 23andMe, ancestry.com and now Helix. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/15/17
BOFA
08/15/17
DOWNGRADE
BOFA
Neutral
Deere downgraded to Neutral from Buy at BofA/Merrill
08/15/17
08/15/17
DOWNGRADE
Target $145

Neutral
Deere downgraded to Neutral ahead of earnings at BofA/Merrill
As previously reported, BofA/Merrill downgraded Deere to Neutral from Buy. Analyst Ross Gilardi is cautious into the print given recent data and expects the pace of earnings performance relative to expectations to begin to subside. The analyst notes recent AEM data reported high horse power tractor demand fell 22% in July and Brazilian combine demand fell 27% in July. Gilardi did not make any change to earnings estimates or his $145 price target ahead of the August 18 report and said the industry will need better grain fundamentals to accelerate growth in second half 2018-2019, which remain an uncertainty.
08/15/17
08/15/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Deere (DE) downgraded to Neutral from Buy at BofA/Merrill with analyst Ross Gilardi saying he is cautious into the print given recent data and expects the pace of earnings performance relative to expectations to begin to subside. 2. Zynerba (ZYNE) was downgraded to Perform from Outperform at Oppenheimer and to Hold from Buy at Jefferies. 3. Uniti Group (UNIT) downgraded to Neutral from Buy at BofA/Merrill with analyst David Barden saying Windstream's (WIN) dividend cut increases concerns about the health of the business and, combined with Uniti's increasing cost of capital, creates a negative feedback loop for the stock. 4. Farmland Partners (FPI) downgraded to Neutral from Outperform at Baird with the firm's analyst saying financial leverage is moving towards 18x EBITDA following the recent preferred offering, and the participating rights could create a liability for the common holders that could grow over time and a common dividend AFFO payout ratio over 130% estimated through YE19. 5. Banco Santander (SAN) downgraded to Neutral from Buy at Goldman Sachs with analyst Jose Abad seeing the valuation as full following the recent outperformance of the shares. The analyst lowered his price target for the shares to EUR 6.40. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
EL Estee Lauder
$98.32

-2.75 (-2.72%)

06/02/17
06/02/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wayfair (W) upgraded to Outperform from Perform at Oppenheimer with analyst Brian Nagel saying the company's sales growth has been reaccelerating lately and its "inventory-light" business model is both powerful and underappreciated. 2. Estee Lauder (EL) and Ulta Beauty (ULTA) were upgraded to Buy from Hold at Jefferies. 3. Deere (DE) upgraded to Neutral from Underweight at JPMorgan with analyst Ann Duignan saying she likes the strategic fit of the Wirtgen Group acquisition and believes it will open up new markets for growth. 4. Jack in the Box (JACK) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jeff Farmer saying the potential sale of the Qdoba concept is not being fully reflected in the shares. 5. Fastenal (FAST) upgraded to Buy from Neutral at Longbow with analyst Chris Dankert saying distribution checks are at the highest level to date trending at 5.3% growth, an acceleration from 4.3% growth reported during March checks. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/06/17
STFL
06/06/17
NO CHANGE
STFL
Estee Lauder stronger focus on specialty retailers will be positive, says Stifel
After meeting with Ulta Beauty (ULTA), Stifel analyst Mark Astrachan says that Estee Lauder's (EL) increased emphasis on specialty retailers " will diversify the company's exposure from weaker channels like U.S. mid-tier department stores. " The analyst quotes Ulta as saying that the launch of Estee's largest brand by Ulta will enable Estee to attract new customers. He expects Ulta to add additional Estee Lauder brands in the future. The analyst raised his price target on Estee Lauder to $108 from $98 and keeps a Buy rating on the stock.
08/09/17
OPCO
08/09/17
NO CHANGE
Target $110
OPCO
Outperform
Estee Lauder [rice target raised to $110 from $100 at Oppenheimer
Oppenheimer analyst Rupesh Parikh raised his price target for Estee Lauder (EL) to $110 from $100 as he still sees the potential for outperformance. Accelerating momentum in key international markets, strong performance of recent acquisitions, strengthening partnerships with Ulta Beauty (ULTA) and Sephora, and the potential for an improved earnings backdrop in 2018 and 2019 could drive further upside in shares, he contends. The analyst reiterates an Outperform rating on Estee Lauder's shares and says he continues to rank it as his top pick across his coverage universe.
08/10/17
UBSW
08/10/17
NO CHANGE
Target $96
UBSW
Neutral
Estee Lauder risk/reward negative heading into Q4 report, says UBS
UBS analyst Stephen Powers noted Estee Lauder shares have risen more than 6% over the past five sessions with no incremental news flow, suggesting any upside from its upcoming earnings report is already priced into the shares. As a result, the risk/reward is more definitely negative. Powers maintained his Neutral rating and $96 price target on Estee Lauder shares ahead of its Q4 report, scheduled for August 18.
FL Foot Locker
$47.70

-0.87 (-1.79%)

08/08/17
08/08/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tesla (TSLA) upgraded to Buy from Hold at Argus with analyst William Selesky saying he expects Tesla to reach breakeven two quarters earlier than he'd previously forecast and sees the company achieving full-year profitability in fiscal 2019. 2. L3 Technologies (LLL) upgraded to Buy from Hold at Drexel Hamilton analyst Pete Skibitski saying he is "cautiously" optimistic that there will be a positive resolution in fiscal 2018 budget negotiations, which will benefit the entire space, and notes L3's international outlook has improved as the year has progressed. 3. Foot Locker (FL) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Jay Sole saying he believes share weakness related to investor concerns surrounding share loss to Amazon (AMZN) and brands' own websites has created an "excellent" buying opportunity. 4. UPS (UPS) upgraded to Buy from Neutral at Citi with analyst Christian Wetherbee saying he sees a "clear path" toward double-digit earnings growth returning in 2018. 5. Cognizant (CTSH) upgraded to Buy from Hold at Berenberg with analyst Georgios Kertsos saying the market now considers U.S. immigration policy changes as unlikely, which leaves upside for investors. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/11/17
SUSQ
08/11/17
NO CHANGE
SUSQ
Positive
Foot Locker, Dick's Sporting weakness a buying opportunity, says Susquehanna
Susquehanna analyst Sam Poser said a noisy first half of 2017 has created compelling buying opportunities for both Foot Locker (FL) and Dick's Sporting (DKS) shares. The analyst said both are best in class companies that should transcend the retail malaise and are positioned to emerge stronger and more profitable. Poser reiterated his Positive rating and $75 price target on Foot Locker and Positive rating and $57 price target on Dick's Sporting shares.
08/15/17
FBRC
08/15/17
NO CHANGE
FBRC
FBR lowers Specialty Retail price targets ahead of Q2 reports
FBR Capital analyst Susan Anderson expects Specialty Retail earnings in Q2 to be overall in-line with consensus estimates, with a lighter top line and gross margin given the need to promote to drive traffic. The analyst views American Eagle (AEO) and L Brands (LB) as winners in the quarter. She upgraded American Eagle this morning to Buy. Anderson also lowered her price target for Neutral-rated Abercrombie & Fitch (ANF) to $11 from $13, for Neutral-rated Ascena Retail (ASNA) to $3 from $5, for Neutral-rated Foot Locker (FL) to $58 from $66, for Neutral-rated Francesca's to $10 from $13, for Neutral-rated Gap (GPS) to $25 from $28 and for Neutral-rated Urban Outfitters (URBN) to $16 from $24.
08/17/17
BARD
08/17/17
NO CHANGE
Target $65
BARD
Outperform
Foot Locker risk/reward to be more favorable following results, says Baird
Baird analyst Jonathan Komp Said the risk/reward for Foot Locker shares are more favorable following Q2 results. The analyst said the valuation is very attractive looking out 6-12 months but the near-term visibility is low suggesting caution heading into upcoming earnings. Komp reiterated his Outperform rating and lowered his price target to $65 from $77 on Foot Locker shares.
HIBB Hibbett Sports
$11.50

-0.3 (-2.54%)

07/24/17
RAJA
07/24/17
NO CHANGE
RAJA
Market Perform
Hibbett warning has negative read-through for Under Armour, says Raymond James
Raymond James analyst Dan Wewer noted that Hibbett Sports' (HIBB) same-store sales warning follows Finish Line's (FINL) Q1 release on June 23 that May sales suffered from weak consumer traffic and difficult product launch comparisons. The read through is negative for Hibbett's vendors, including Under Armour (UAA), said Wewer, who added that it also appears negative for Dick's Sporting Goods (DKS), though he is not sure if Hibbett's sales trends were company specific or reflective of the industry.
07/25/17
ADAM
07/25/17
NO CHANGE
Target $14
ADAM
Hold
Hibbett Sports price target lowered to $14 from $22 at Canaccord
Canccord analyst Camilo Lyon lowered his price target on Hibbett Sports to $14 from $22 following the company's pre-announcement of "stunningly poor" results. The analyst noted the company expects Q2 comps to be down 10% along with significant gross margin pressure. The weakness was mainly due to a footwear miss led by decelerating in basketball and running, said Lyon, who maintained his Hold rating on Hibbett shares.
07/25/17
FBCO
07/25/17
NO CHANGE
Target $14
FBCO
Underperform
Hibbett Sports price target lowered to $14 from $24 at Credit Suisse
Credit Suisse analyst Seth Sigman lowered his price target for Hibbett Sports to $14 from $24 after the company preannounced weaker Q2 results, dragged down by comps, related expense deleverage and much weaker gross margins. The analyst adds that results reflect weak demand, growing online competition along with elevated investment requirements as the company launches its first transactional website. He reiterates an Underperform rating on the shares.
08/01/17
FBCO
08/01/17
NO CHANGE
Target $52
FBCO
Neutral
Foot Locker price target lowered to $52 from $66 at Credit Suisse
Credit Suisse analyst Christian Buss lowered his price target for Foot Locker (FL) to $52 from $66 given increasing industry headwinds and following disappointing commentary by peers Finish Line (FINL) and Hibbett Sports (HIBB). The analyst believes the best-in-class execution by Foot Locker may no longer be enough. He reiterates a Neutral rating on Foot Locker's shares.

TODAY'S FREE FLY STORIES

EGHT

8x8, Inc.

$13.65

-0.15 (-1.09%)

10:35
09/20/17
09/20
10:35
09/20/17
10:35
Hot Stocks
8x8, Inc. enters partnership with Aryaka »

Aryaka and 8x8, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

  • 16

    Nov

APC

Anadarko

$44.64

0.88 (2.01%)

10:35
09/20/17
09/20
10:35
09/20/17
10:35
Options
Anadarko put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

JCOM

j2 Global

$73.37

-1.52 (-2.03%)

10:35
09/20/17
09/20
10:35
09/20/17
10:35
Conference/Events
j2 Global management to meet with JMP Securities »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 28

    Sep

PFE

Pfizer

$35.85

0.4 (1.13%)

, JNJ

Johnson & Johnson

$133.60

-1.62 (-1.20%)

10:34
09/20/17
09/20
10:34
09/20/17
10:34
Hot Stocks
Pfizer takes J&J to court as analysts shake up pharma ratings »

Morgan Stanley analyst…

PFE

Pfizer

$35.85

0.4 (1.13%)

JNJ

Johnson & Johnson

$133.60

-1.62 (-1.20%)

LLY

Eli Lilly

$82.24

0.505 (0.62%)

NVS

Novartis

$86.11

0.26 (0.30%)

ABBV

AbbVie

$86.90

0.53 (0.61%)

BMY

Bristol-Myers

$63.08

0.1532 (0.24%)

AGN

Allergan

$211.28

-3.725 (-1.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 22

    Sep

  • 22

    Sep

  • 24

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 17

    Oct

  • 18

    Oct

  • 26

    Oct

  • 31

    Oct

  • 09

    Nov

  • 05

    Mar

  • 17

    May

10:31
09/20/17
09/20
10:31
09/20/17
10:31
General news
Crude inventories for week of September 15 »

Crude oil inventories…

PYPL

PayPal

$63.83

0.91 (1.45%)

10:30
09/20/17
09/20
10:30
09/20/17
10:30
Recommendations
PayPal analyst commentary  »

PayPal price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 22

    Oct

  • 29

    Nov

10:30
09/20/17
09/20
10:30
09/20/17
10:30
General news
The 1.7% U.S. August existing home sales drop »

The 1.7% U.S. August…

AAXN

Axon

$22.07

-0.33 (-1.47%)

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Periodicals
Studies about Taser's safety were overstated, Reuters reports »

Claims about early…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$317.93

-0.25 (-0.08%)

, CBAY

CymaBay

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

BIIB

Biogen

$317.93

-0.25 (-0.08%)

CBAY

CymaBay

EVH

Evolent Health

$16.18

0.5299 (3.39%)

EPZM

Epizyme

$19.25

1.4 (7.84%)

INTU

Intuit

$145.34

1.54 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 03

    Oct

  • 22

    Oct

  • 25

    Oct

JNJ

Johnson & Johnson

$133.80

-1.42 (-1.05%)

, UAL

United Continental

$58.01

0.47 (0.82%)

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

JNJ

Johnson & Johnson

$133.80

-1.42 (-1.05%)

UAL

United Continental

$58.01

0.47 (0.82%)

IR

Ingersoll-Rand

$88.85

-1.61 (-1.78%)

LB

L Brands

$37.40

-1.83 (-4.66%)

YAHOY

Yahoo Japan

$9.02

-0.03 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 27

    Sep

  • 02

    Oct

  • 17

    Oct

PFE

Pfizer

$35.91

0.455 (1.28%)

, PGR

Progressive

$47.57

-0.065 (-0.14%)

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

PFE

Pfizer

$35.91

0.455 (1.28%)

PGR

Progressive

$47.57

-0.065 (-0.14%)

AAL

American Airlines

$44.38

-0.93 (-2.05%)

LUV

Southwest

$53.77

0.23 (0.43%)

POST

Post Holdings

$86.68

0.32 (0.37%)

NDSN

Nordson

$114.62

0.12 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 02

    Oct

  • 18

    Oct

  • 31

    Oct

CELC

Celcuity

10:29
09/20/17
09/20
10:29
09/20/17
10:29
Syndicate
Celcuity opens at $12.35, IPO priced at $9.50 per share »

Celcuity (CELC) priced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

WDC

Western Digital

$89.92

0.74 (0.83%)

, TOSBF

Toshiba, also use TOSYY

$2.89

0.01 (0.35%)

10:28
09/20/17
09/20
10:28
09/20/17
10:28
Recommendations
Western Digital, Toshiba, also use TOSYY analyst commentary  »

Western Digital…

WDC

Western Digital

$89.92

0.74 (0.83%)

TOSBF

Toshiba, also use TOSYY

$2.89

0.01 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$81.07

-0.12 (-0.15%)

10:25
09/20/17
09/20
10:25
09/20/17
10:25
Conference/Events
Medtronic has conference call hosted by Leerink »

Leerink to hold a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

PPC

Pilgrim's Pride

$28.91

-0.63 (-2.13%)

10:25
09/20/17
09/20
10:25
09/20/17
10:25
Conference/Events
Pilgrim's Pride holds an investor day »

President and Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

DESP

Despegar.com

10:21
09/20/17
09/20
10:21
09/20/17
10:21
Syndicate
Breaking Syndicate news story on Despegar.com »

Despegar.com opens at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

AAPL

Apple

$158.73

0.06 (0.04%)

10:20
09/20/17
09/20
10:20
09/20/17
10:20
Options
Heavy trading in Apple as shares come under fire Wednesday »

Heavy trading in Apple as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 22

    Oct

10:20
09/20/17
09/20
10:20
09/20/17
10:20
General news
Treasury Action: yields remained elevated »

Treasury Action: yields…

CVX

Chevron

$116.75

0.405 (0.35%)

10:19
09/20/17
09/20
10:19
09/20/17
10:19
Periodicals
Chevron drills well in Iraqi Kurdish area after two-year interlude, Reuters says »

Despite an international…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 09

    Nov

DESP

Despegar.com

10:19
09/20/17
09/20
10:19
09/20/17
10:19
Syndicate
Breaking Syndicate news story on Despegar.com »

Despegar.com IPO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

$NSD

NASDAQ Market Internals

10:17
09/20/17
09/20
10:17
09/20/17
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

10:16
09/20/17
09/20
10:16
09/20/17
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DFFN

Diffusion Pharmaceuticals

$1.75

-0.01 (-0.57%)

10:16
09/20/17
09/20
10:16
09/20/17
10:16
Hot Stocks
Diffusion Pharmaceuticals granted European patent for bipolar trans carotenoids 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
09/20/17
09/20
10:15
09/20/17
10:15
General news
U.S. existing home sales dropped 1.7% to 5.35 M in August »

U.S. existing home sales…

10:15
09/20/17
09/20
10:15
09/20/17
10:15
General news
Breaking General news story  »

Week of 9/15 EIA…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.